Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Pulmonary Fibrosis Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases Lung Diseases, Interstitial Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Local Institution - 0003, Mar del Plata, B, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must have completed participation in either IM027068 or IM0271015 (defined as receiving study intervention (IMP) until completion of EOT visit).

Exclusion criteria

  • Clinically significant AE that resulted in discontinuation or interruption of IMP (Investigational Medicinal Product) in IM027068 or IM0271015 without reinitiation of IMP.
  • Exhibit symptoms of heart failure at rest.
  • History of lung reduction surgery or lung transplant. Note: Being on the transplantation list is allowed.
  • Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single drug therapy that now requires multi-drug therapy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

Treatment and study plan

BMS-986278

Drug

Specified dose on specified days

Other names: Admilparant

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to Week 100

  2. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: Up to Week 100

  3. Number of Participants With AEs leading to Discontinuation

    Time frame: Up to Week 100

  4. Number of Participants With AEs leading to Deaths

    Time frame: Up to Week 100

  5. Number of Participants With Clinically Significant Laboraty Abnormalities

    Time frame: Up to Week 100

  6. Number of Participants With Clinically Significant Electocardiogram (ECG) Abnormalities

    Time frame: Up to Week 100

  7. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Time frame: Up to Week 100

Study contacts

Contact information is provided by the study sponsor or research team.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

[email protected]

855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Mar 2, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.